WOOJUNG BIO, Inc. (KOSDAQ:215380)
South Korea · Delayed Price · Currency is KRW 2,450.00
-255.00 (-9.43%)
At close: Apr 2, 2026
WOOJUNG BIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 37,587 | 43,200 | 38,616 | 46,918 | 31,238 |
Other Revenue | - | - | -0 | - | - |
| 37,587 | 43,200 | 38,616 | 46,918 | 31,238 | |
Revenue Growth (YoY) | -12.99% | 11.87% | -17.70% | 50.20% | -16.35% |
Cost of Revenue | 27,583 | 30,613 | 32,427 | 40,291 | 25,490 |
Gross Profit | 10,004 | 12,586 | 6,189 | 6,626 | 5,748 |
Selling, General & Admin | 11,028 | 8,522 | 8,287 | 6,881 | 7,686 |
Research & Development | 443.61 | 505.84 | 294.44 | 614.06 | 538.26 |
Amortization of Goodwill & Intangibles | 32.74 | 57.14 | 67.49 | 68.09 | 61.99 |
Other Operating Expenses | 257.46 | 232.96 | 218.17 | 202.1 | 196.91 |
Operating Expenses | 13,658 | 10,802 | 10,213 | 9,148 | 9,609 |
Operating Income | -3,655 | 1,785 | -4,025 | -2,521 | -3,861 |
Interest Expense | -2,892 | -3,228 | -3,225 | -2,797 | -648.62 |
Interest & Investment Income | 68.26 | 31.72 | 55.26 | 78 | 51.23 |
Earnings From Equity Investments | -2.31 | -3 | - | - | - |
Currency Exchange Gain (Loss) | -116.15 | -50.28 | -37.65 | -45.53 | 68.61 |
Other Non Operating Income (Expenses) | 1,871 | 1,248 | 3,953 | 4,358 | 1,336 |
EBT Excluding Unusual Items | -4,727 | -217.38 | -3,280 | -927.89 | -3,054 |
Gain (Loss) on Sale of Investments | -130.06 | -44.33 | 5.51 | -28.94 | 1,182 |
Gain (Loss) on Sale of Assets | 181.47 | -48.6 | 27.2 | -61.77 | -53.59 |
Asset Writedown | -693.21 | 560.38 | - | -846.94 | - |
Other Unusual Items | -178.12 | -24.77 | -1,807 | - | - |
Pretax Income | -5,547 | 225.3 | -5,054 | -1,866 | -1,926 |
Income Tax Expense | - | - | - | 14.66 | - |
Net Income | -5,547 | 225.3 | -5,054 | -1,880 | -1,926 |
Net Income to Common | -5,547 | 225.3 | -5,054 | -1,880 | -1,926 |
Shares Outstanding (Basic) | 17 | 15 | 13 | 13 | 12 |
Shares Outstanding (Diluted) | 17 | 15 | 16 | 13 | 12 |
Shares Change (YoY) | 10.90% | -4.46% | 22.07% | 7.66% | 3.36% |
EPS (Basic) | -333.00 | 15.00 | -394.87 | -146.00 | -161.00 |
EPS (Diluted) | -333.00 | 15.00 | -451.00 | -146.00 | -161.00 |
Free Cash Flow | -884.46 | -1,419 | -4,065 | -8,919 | -34,956 |
Free Cash Flow Per Share | -53.10 | -94.47 | -258.57 | -692.61 | -2922.44 |
Gross Margin | 26.61% | 29.13% | 16.03% | 14.12% | 18.40% |
Operating Margin | -9.72% | 4.13% | -10.42% | -5.37% | -12.36% |
Profit Margin | -14.76% | 0.52% | -13.09% | -4.01% | -6.17% |
Free Cash Flow Margin | -2.35% | -3.28% | -10.53% | -19.01% | -111.90% |
EBITDA | 116.94 | 5,986 | 298.17 | 1,726 | -1,160 |
EBITDA Margin | 0.31% | 13.86% | 0.77% | 3.68% | -3.71% |
D&A For EBITDA | 3,772 | 4,202 | 4,323 | 4,247 | 2,701 |
EBIT | -3,655 | 1,785 | -4,025 | -2,521 | -3,861 |
EBIT Margin | -9.72% | 4.13% | -10.42% | -5.37% | -12.36% |
Advertising Expenses | 95.72 | 104.22 | 50.59 | 95.36 | 48.75 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.